Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Northland Securities Inc.

Northland Securities Inc. lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 100.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,000 shares of the medical equipment provider’s stock after acquiring an additional 6,000 shares during the quarter. Zimmer Biomet accounts for about 1.0% of Northland Securities Inc.’s portfolio, making the stock its 21st largest position. Northland Securities Inc.’s holdings in Zimmer Biomet were worth $1,082,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. DV Equities LLC acquired a new position in Zimmer Biomet during the 4th quarter worth $25,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet during the 4th quarter worth about $30,000. Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $31,000. Flagship Harbor Advisors LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $32,000. Finally, Grove Bank & Trust boosted its stake in shares of Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 328 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.28% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ZBH. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Monday, July 6th. Citigroup decreased their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Citizens Jmp lowered their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a report on Wednesday, April 29th. JPMorgan Chase & Co. dropped their price objective on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 29th. Finally, Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $102.33.

Zimmer Biomet Trading Up 3.0%

NYSE:ZBH opened at $94.09 on Tuesday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The stock has a market cap of $18.20 billion, a P/E ratio of 24.44, a P/E/G ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The stock has a 50-day simple moving average of $86.49 and a 200-day simple moving average of $89.80.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the company earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s payout ratio is currently 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.